Eckhard Niemeler Joins Nouscom As Chief Business Officer

Nouscom appoints Eckhard Niemeler as CBO to drive growth and strategic partnerships, advancing its neoantigen cancer immunotherapy pipeline.

Simantini Singh Deo | Dec 03, 2024

Spyre Launches Phase 1 Trials For Anti-TL1A Inflammatory Bowel Disease Therapy

Spyre Therapeutics begins Phase 1 trials for two anti-TL1A antibodies, aiming to advance innovative treatments for inflammatory bowel disease.

Simantini Singh Deo | Dec 03, 2024

AI in Pharma

AC Health Partners with USAID to Expand HIV Care in the Philippines

AC Health and USAID join forces to enhance HIV prevention, testing, and treatment, expanding access to life-saving care across the Philippines.

Mrudula Kulkarni | Dec 03, 2024

AI in Pharma

Medexus Pharmaceuticals Amends U.S. License Agreement for Treosulfan

Medexus amends its treosulfan agreement, adjusting milestone payments and gaining financial flexibility ahead of expected FDA approval in early 2025.

Mrudula Kulkarni | Dec 03, 2024

AI in Pharma

TORL BioTherapeutics Appoints Aran Maree, M.D., As New Chief Medical Officer

TORL BioTherapeutics appoints Dr. Aran Maree as CMO and launches Phase 2 study of TORL-1-23 for CLDN6+ platinum-resistant ovarian cancer.

Simantini Singh Deo | Dec 03, 2024

Rigel’s R289 Gains FDA Fast Track For Fighting Lower-Risk MDS

Rigel's R289 earns FDA Fast Track for lower-risk MDS, aiming to address unmet needs in transfusion-dependent patients with limited options.

Simantini Singh Deo | Dec 03, 2024

PTC And Novartis Collab For Huntington's Disease Therapy

PTC Therapeutics and Novartis join forces for the Huntington's Disease Therapy.

Simantini Singh Deo | Dec 03, 2024